NJH395
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NON-breast HER2+ Malignancies
Conditions
NON-breast HER2+ Malignancies
Trial Timeline
Dec 27, 2018 → Oct 19, 2020
NCT ID
NCT03696771About NJH395
NJH395 is a phase 1 stage product being developed by Novartis for NON-breast HER2+ Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT03696771. Target conditions include NON-breast HER2+ Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03696771 | Phase 1 | Completed |